Akeso falls 6% as FDA declines ivonescimab U.S. application

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Akeso (9926.HK) fell more than 6% in Hong Kong trading to HK$57.30.

The biotechnology industry index fell 3.9% over the same period.

The U.S. Food and Drug Administration declined the initial marketing application for ivonescimab, citing that 93% of trial data came from Chinese patients, which limits applicability to the U.S. population. The FDA had previously raised concerns about enrollment practices, noting delayed recruitment in North America and Europe. The stock tumbled 22.11% the previous day, erasing about HK$17 billion in market value.

Chairman Xia Yu acknowledged shortcomings in the trial design and said the rejection applies only to a specific later-line indication. Global clinical development and key HARMONi-3 data readouts remain unaffected, and the company is considering share buybacks to stabilize the market.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.